# 3.2.1.1 Infections leading to death (Grade 5)

**Page range:** 27â€“28

```text
3.2.1.1
Infections leading to death (Grade 5)
A total of five (5/108; 4.6%) subjects developed five fatal events of infections in the
pralsetinib treatment arm (Table 3). The reported PTs included Pneumonia (n=3), lower
respiratory tract infection (n=1) and sepsis (n=1).
No fatal events related to infections were reported in the comparator treatment arm.
Table 6 presents an overview of the subjects with fatal infections in the pralsetinib
treatment arm:

8 Grade 3-4 Pneumonia includes PTs of Pneumonia (n=7), Pneumocystis jirovecii pneumonia (n=3),
Pneumonia cytomegaloviral (n=2) and Pneumonia legionella (n=1).

28
Drug Safety Report No: 1132062
Table 6
Overview of Subjects with Fatal Infections in the Pralsetinib
Treatment Arm for the AcceleRET-Lung study (N=5)
Patient Number
Age/Sex
Ethnicity/Country
Indication
MedDRA PT of Fatal AE
Time to Event Onset (in
days)
Day of Death
Action taken with Pralsetinib
Causality (as per
investigator)
3302/012
57/Male
Asian/Korea, republic of
Non-small cell lung cancer
Pneumonia
SD 58
SD 71
Drug withdrawn
Not related
4201/0029
76/Female
Unknown/France
Non-small cell lung cancer
metastatic
Pneumonia
SD 30
SD 39
Dose not changed
Not related
4508/00310
72/Male
White/ Spain
Non-small cell lung cancer
metastatic
Sepsis
SD 155
SD 155
Drug withdrawn
Not related
4701/001
33/Female
White/ United Kingdom
Non-small cell lung cancer
metastatic
Lower respiratory tract
infection
SD 51
SD 60
Drug withdrawn
Related
7201/001
70/Female
American Indian or Alaska
native/ Costa Rica
Non-small cell lung cancer
metastatic
Pneumonia
SD 25
SD 26
Dose not changed
Not related
MedDRA Version 27.0. SD: Study Day
Clinical Output Source:
root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVI
NF_SE.out
Of the five fatal infection events in pralsetinib arm 5/108 (4.6%), three fatal events of
pneumonia were reported in 3/108 (2.8%) patients (2 females and one male), aged 57 to
76 years. These three events were reported from Costa Rica, France, and Korea,
Republic of (n=1 each). All patients had received pralsetinib for non-small cell lung
cancer/ metastatic. The time to onset ranged from 25, 30 and 58 days. All the three

```